• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TH-MYCN 转基因小鼠神经母细胞瘤细胞程序性细胞死亡-1 的表达。

Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice.

机构信息

Department of Pediatric Surgery, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.

出版信息

Pediatr Surg Int. 2022 Nov 28;39(1):6. doi: 10.1007/s00383-022-05292-y.

DOI:10.1007/s00383-022-05292-y
PMID:36441248
Abstract

BACKGROUND

Immunotherapy may improve the poor prognosis of high-risk neuroblastoma. Programmed cell death-1 (PD-1) is expressed in several cancers. The tyrosine hydroxylase MYCN (TH-MYCN) transgenic mouse model is widely used in neuroblastoma research, but detailed information on its immunological background is lacking. Therefore, we studied the immunological tumor microenvironment and tumor cell surface antigen expression in homozygote and hemizygote mice and effects of antibody therapy against PD-1.

METHODS

CD4, CD8, CD11b, and CD11c expression in immune cells from retroperitoneal lymph nodes and spleen was analyzed by flow cytometry. Tumor cell surface antigen expression was confirmed, and data from homozygote and hemizygote mice were compared. Effects of anti-PD-1 antibody were evaluated.

RESULTS

CD4-, CD8-, CD11b-, and CD11c-positive cells were not significantly different in homozygote and hemizygote mice, and CD11b- and CD11c-positive cells were identified in the tumor microenvironment in both. Tumor cells expressed PD-1, and anti-PD-1 antibody had anti-tumor effects and significantly reduced the percentage of living tumor cells in cultures after 2 h.

CONCLUSION

The immunological background is similar in homozygote and hemizygote TH-MYCN transgenic mice, and both have PD-1-positive tumor cells. Anti-PD-1 antibody suppresses tumor growth. This mouse model may be a useful for studying immunotherapy of neuroblastoma.

摘要

背景

免疫疗法可能改善高危神经母细胞瘤的预后不良。程序性细胞死亡受体-1(PD-1)在几种癌症中表达。酪氨酸羟化酶 MYCN(TH-MYCN)转基因小鼠模型广泛用于神经母细胞瘤研究,但缺乏其免疫学背景的详细信息。因此,我们研究了同型和杂合子小鼠的免疫肿瘤微环境和肿瘤细胞表面抗原表达,以及抗 PD-1 抗体治疗的效果。

方法

通过流式细胞术分析腹膜后淋巴结和脾脏免疫细胞中 CD4、CD8、CD11b 和 CD11c 的表达。确认肿瘤细胞表面抗原的表达,并比较同型和杂合子小鼠的数据。评估抗 PD-1 抗体的效果。

结果

同型和杂合子小鼠的 CD4+、CD8+、CD11b+和 CD11c+细胞无明显差异,且两者的肿瘤微环境中均存在 CD11b+和 CD11c+细胞。肿瘤细胞表达 PD-1,抗 PD-1 抗体具有抗肿瘤作用,可显著减少培养 2 小时后存活肿瘤细胞的比例。

结论

TH-MYCN 转基因同型和杂合子小鼠的免疫学背景相似,两者均有 PD-1 阳性肿瘤细胞。抗 PD-1 抗体抑制肿瘤生长。该小鼠模型可能有助于研究神经母细胞瘤的免疫疗法。

相似文献

1
Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice.TH-MYCN 转基因小鼠神经母细胞瘤细胞程序性细胞死亡-1 的表达。
Pediatr Surg Int. 2022 Nov 28;39(1):6. doi: 10.1007/s00383-022-05292-y.
2
The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model.BET 蛋白抑制剂 JQ1 降低缺氧水平并提高抗 PD-1 在高危神经母细胞瘤小鼠模型中的治疗获益。
Cells. 2022 Sep 6;11(18):2783. doi: 10.3390/cells11182783.
3
Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.TH-MYCN 小鼠神经母细胞瘤模型中的肿瘤发生、生长特征和遗传异常谱。
PLoS One. 2012;7(12):e51297. doi: 10.1371/journal.pone.0051297. Epub 2012 Dec 17.
4
A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.用于神经母细胞瘤临床前免疫研究的 C57Bl/6 小鼠可移植的 TH-MYCN 转基因肿瘤模型。
Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.
5
Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.免疫检查点抑制后,树突状细胞浸润小鼠神经母细胞瘤Neuro-2a。
J Surg Res. 2020 Sep;253:201-213. doi: 10.1016/j.jss.2020.03.059. Epub 2020 May 4.
6
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.PD-L1 是溴结构域抑制剂 JQ1 的治疗靶点,与 HLA Ⅰ类分子联合是神经母细胞瘤有前途的预后生物标志物。
Clin Cancer Res. 2017 Aug 1;23(15):4462-4472. doi: 10.1158/1078-0432.CCR-16-2601. Epub 2017 Mar 7.
7
tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.肿瘤而非肿瘤衍生细胞系具有肾上腺素能谱系特征,GD2+,并且对抗 GD2 抗体治疗有反应。
Oncoimmunology. 2022 May 24;11(1):2075204. doi: 10.1080/2162402X.2022.2075204. eCollection 2022.
8
Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.TH-MYCN 转基因小鼠的神经母细胞瘤天然抗体与自发消退无关。
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1666-1673. doi: 10.1016/j.bbrc.2018.07.097. Epub 2018 Jul 24.
9
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.从 TH-MYCN 转基因小鼠肿瘤中建立的细胞系中 p53 通路的特征。
Int J Oncol. 2018 Mar;52(3):967-977. doi: 10.3892/ijo.2018.4261. Epub 2018 Jan 31.
10
miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.miRNA 表达谱分析揭示了鼠 TH-MYCN 神经母细胞瘤模型与人类肿瘤的相似性,并确定了新的候选 miRNA。
PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

本文引用的文献

1
Monoclonal Antibody Therapies for High Risk Neuroblastoma.用于高危神经母细胞瘤的单克隆抗体疗法
Biologics. 2021 Jun 9;15:205-219. doi: 10.2147/BTT.S267278. eCollection 2021.
2
Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future.神经母细胞瘤的免疫治疗策略:现状、过去与未来
Vaccines (Basel). 2021 Jan 13;9(1):43. doi: 10.3390/vaccines9010043.
3
Immune characterization of pre-clinical murine models of neuroblastoma.神经母细胞瘤临床前小鼠模型的免疫特征。
Sci Rep. 2020 Oct 7;10(1):16695. doi: 10.1038/s41598-020-73695-9.
4
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.纳武利尤单抗治疗复发或难治性实体瘤或淋巴瘤的儿童和青年患者(ADVL1412):一项多中心、开放标签、单臂、1-2 期临床试验。
Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17.
5
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.肿瘤细胞内在的 PD-1 受体是一种肿瘤抑制因子,并介导对 PD-1 阻断治疗的耐药性。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650. doi: 10.1073/pnas.1921445117. Epub 2020 Mar 11.
6
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?PD-1/PD-L1 阻断在儿科癌症中的应用:未来前景如何?
Cancer Lett. 2019 Aug 10;457:74-85. doi: 10.1016/j.canlet.2019.04.025. Epub 2019 May 2.
7
DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-Induced Arthritis Through an Nrf2-p62-Keap1 Feedback Loop.DC32,一种双氢青蒿素衍生物,通过 Nrf2-p62-Keap1 反馈环改善胶原诱导性关节炎。
Front Immunol. 2018 Nov 27;9:2762. doi: 10.3389/fimmu.2018.02762. eCollection 2018.
8
Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.TH-MYCN 转基因小鼠的神经母细胞瘤天然抗体与自发消退无关。
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1666-1673. doi: 10.1016/j.bbrc.2018.07.097. Epub 2018 Jul 24.
9
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.肿瘤表达的PD-1的阻断促进肺癌生长。
Oncoimmunology. 2018 Jan 29;7(4):e1408747. doi: 10.1080/2162402X.2017.1408747. eCollection 2018.
10
Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1.程序性细胞死亡受体 1(PD-1)检查点阻断联合哺乳动物雷帕霉素靶蛋白抑制剂可抑制肝癌细胞内在 PD-1 诱导的肝细胞癌生长。
Hepatology. 2017 Dec;66(6):1920-1933. doi: 10.1002/hep.29360.